Molecular response milestones to be achieved and maintained in first- and second-line TKI therapy for optimal response to be defined according to the ELN. BCR::ABL1 KD mutation testing may provide useful information if such milestones are missed. KD, kinase domain; m, months; TKI, tyrosine kinase inhibitor.